Forecast 2005 - Pharmaceutical Executive

ADVERTISEMENT

Forecast 2005
This is the time of year to not only reflect on the past, but to ponder the future. Forget soothsayers, prophets, and fortune tellers' crystal balls. Inside are predictions from some of industry's key thought leaders.

Pharmaceutical Executive


18. If a drug importation bill—or the threat of one—does not reduce the price differential between US, Canadian, and European drug prices, Congress will look for other ways to do so.

19. Drug companies will start to take a tougher line with some foreign governments on drug pricing, including walking away from some countries.


Companies' pricing strategies will become less aggressive.
20. Industry's pricing in the United States will be less aggressive as companies seek to diminish demonization.

PHARM EXEC SAYS: » Midsize players with targeted therapeutics may begin to merge and threaten the dominance of some big pharmas, which are struggling to prove that blockbusters are safe and are paying large sums to those who think otherwise.

L.J.SELLER, SENIOR EDITOR

» Jane Sarasohn-Kahn, MA, MHSA Management consultant and health economist

In 2005, the driving forces shaping the outlook for inrormation technology in the pharmaceutical marketplace include the demand for monitoring and measuring healthcare quality and patient outcomes; growing concern about a safer pharma supply chain; and the global demand for transparency. Together, these drivers converge toward the following events:

E-prescribing comes of age. Health plans—both private and public—are arming physicians with PDAs and personal computers to enable e-prescribing (eRx). CaféRx, an alliance of Allscripts, Cisco, HP, Microsoft, NCPDP, NDCHealth, and others, will provide end-to-end eRx capability. This initiative could be eRx's tipping point. Health plans and payers will benefit as physicians have formulary information, including available generic substitutes, for each patient at the point of prescribing.

Integration across silos. Payers and providers are increasingly able to marry patient data from different sources. As claims data can be integrated with patient outcomes data (for example, employer's return-to-work statistics with patients' perceived quality of life), payers and plans will be able to compare the true cost-effectiveness of various treatments. Groups such as the National Business Coalition on Health have begun to study this process.

RFID goes beyond Wal-Mart. Importation of pharmaceuticals in the United States has gained bipartisan support in Congress. To ensure a safe supply chain, pharmaceutical manufacturers, distributors, and retail pharmacies will come together to adopt the first stages of RFID across the supply chain.


Public and private health plans will offer end-to-end electronic prescribing.
Clinical trials online. The call for greater transparency of clinical trials influential peer-reviewed medical journals will usher in a new phase of online clinical information that can be used by patients, clinicians, and others interested in delving into greater details learned in trials. The level of details published online has yet to be negotiated, which will happen in a careful dance involving publishers, researchers, and their respective lawyers.

PHARM EXEC SAYS: » Cost consciousness will rise again and again—not only among consumers. Pharma will tighten its belt to compensate for the squeeze on profits.

MICHAELD. LAM, ASSOCIATE EDIOTER


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here